240JPY
25.70 BJPY
690.46 BJPY
66.16 M
About SUNDRUG CO LTD
Sector
Industry
Headquarters
Tokyo
Website
Employees (FY)
6.37 K
Founded
1957
ISIN
JP3336600006
FIGI
BBG000DDGHH3
Sundrug Co., Ltd. engages in the pharmaceutical business. It operates through the Drug Store and Discount Store segments. The Drug Store segment sells pharmaceutical products, cosmetics, and general merchandise. The Discount Store segment offers household goods and food products. The company was founded by Yukimasa Tada in December 1957 and is headquartered in Tokyo, Japan.
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Frequently Asked Questions
The current price of 9989 is 4522 JPY — it has decreased by 0.07% in the past 24 hours.
Depending on the exchange, the stock ticker may vary. For instance, on TSE exchange SUNDRUG CO LTD stocks are traded under the ticker 9989.
SUNDRUG CO LTD is going to release the next earnings report on May 15, 2024. Keep track of upcoming events with our Earnings Calendar.
9989 stock is 2.01% volatile and has beta coefficient of 0.68. Check out the list of the most volatile stocks — is SUNDRUG CO LTD there?
9989 earnings for the last quarter are 61.18 JPY per share, whereas the estimation was 59.17 JPY resulting in a 3.39% surprise. The estimated earnings for the next quarter are 74.83 JPY per share. See more details about SUNDRUG CO LTD earnings.
SUNDRUG CO LTD revenue for the last quarter amounts to 189.56 B JPY despite the estimated figure of 188.83 B JPY. In the next quarter revenue is expected to reach 195.44 B JPY.
Yes, you can track SUNDRUG CO LTD financials in yearly and quarterly reports right on TradingView.
9989 stock has risen by 1.53% compared to the previous week, the month change is a 5.20% fall, over the last year SUNDRUG CO LTD has showed a 21.56% increase.
9989 net income for the last quarter is 8.73 B JPY, while the quarter before that showed 7.15 B JPY of net income which accounts for 21.99% change. Track more SUNDRUG CO LTD financial stats to get the full picture.
Today SUNDRUG CO LTD has the market capitalization of 529.21 B, it has decreased by 0.05% over the last week.
SUNDRUG CO LTD dividend yield was 2.75% in 2022, and payout ratio reached 45.49%. The year before the numbers were 2.39% and 34.80% correspondingly. See high-dividend stocks and find more opportunities for your portfolio.
Like other stocks, 9989 shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade SUNDRUG CO LTD stock right from TradingView charts — choose your broker and connect to your account.
As of Apr 25, 2024, the company has 6.37 K employees. See our rating of the largest employees — is SUNDRUG CO LTD on this list?
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So SUNDRUG CO LTD technincal analysis shows the buy rating today, and its 1 week rating is buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating SUNDRUG CO LTD stock shows the buy signal. See more of SUNDRUG CO LTD technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.
We've gathered analysts' opinions on SUNDRUG CO LTD future price: according to them, 9989 price has a max estimate of 5700.00 JPY and a min estimate of 4520.00 JPY. Read a more detailed SUNDRUG CO LTD forecast: see what analysts think of SUNDRUG CO LTD and suggest that you do with its stocks.
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. SUNDRUG CO LTD EBITDA is 55.48 B JPY, and current EBITDA margin is 7.17%. See more stats in SUNDRUG CO LTD financial statements.